 |
|
Lyme DiseaseShift the Paradigm!
Charles Ellenbogen, MD
Arch Fam Med. 1997;6(2):191-195.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Shadick NA, Phillips CB, Logigian EL, et at. The long-term clinical outcomes of Lyme disease: a population-based retrospective cohort study. Ann Intern Med. 1994;121:560-567.
FREE FULL TEXT
2. Steere AC, Taylor E, McHugh GL, Logigian EL. Overdiagnosis of Lyme disease. JAMA. 1993;269:1812-1816.
FREE FULL TEXT
3. DeMonco C. The Lyme threat. American Lyme Disease Alliance Newslett. Winter/Spring 1993:4, 6.
4. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953-959.
FREE FULL TEXT
5. Pollack RJ, Komaroff AL, Telford III SR, et al. Borrelia burgdorferi infection is rarely found in patients with chronic fatigue syndrome. Clin Infect Dis. 1995;20:467-468.
PUBMED
6. Sigal LH. Management of Lyme disease refractory to antibiotic therapy. Rheum Dis Clin North Am. 1995;21:217-230.
PUBMED
7. Marchesani RB. Diagnosing errors reinforce Lyme disease fears. Infect Dis Newslett. 1992;5:10-11.
8. Wetherill PE, Schoen RT. Clinical manifestations of Lyme disease. Mediguide to Infectious Diseases. New York, NY: Lawrence DellaCorte Publications Inc; 1995;15:1-5.
9. Steere AC. Borrelia burgdorferi (Lyme disease, Lyme borreliosis). In: Mandell GL, Bennet JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone Inc; 1995:2143-2155. 10. Aruero-Rosenfeld ME, Nowakowski J, McKenna DF, et al. Serodiagnosis in early Lyme disease. J Clin Microbiol. 1993;31:3090-3095.
FREE FULL TEXT
11. Ley C, Le C, Olshen EM, Reingold AL. The use of serologic tests for Lyme disease in a prepaid health plan in California. JAMA. 1994;271:460-463.
FREE FULL TEXT
12. Association of State and Territorial Public Health Laboratory Directors. Proceedings of the Second National Conference on Serologic Diagnosis of Lyme Disease. Washington, DC: Association of State and Territorial Public Health Laboratory Directors; October 27-29, 1994:1-7. 13. Gamstorp I. Lyme borreliosis from a patient's viewpoint. Scand J Infect Dis Suppl. 1991;77:15-16.
PUBMED
14. Berger BW. Dermatologic manifestations of Lyme disease. Rev Infect Dis. 1989;11(suppl_6):S1475-S1481.
PUBMED
15. Engstrom SM, Shoop E, Johnson RC. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol. 1995;33:419-427.
ABSTRACT
16. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis. 1993;167:392-400.
PUBMED
17. Preac-Murisc V, Weber K, Pfister HW, et al. Survival of Borrelia burgdorferiin antibiotically treated patients with Lyme borreliosis. Infection. 1989;17:355-359.
PUBMED
18. Steere AC, Levin RE, Mollow PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum. 1994;37:878-888.
PUBMED
19. Nadelman RB, Nowakowski J, Forseter G, et al. Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. Am J Med. 1993;94:583-588.
PUBMED
20. Nocton JJ, Dressler F, Rutlege BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med. 1994;330:229-234.
FREE FULL TEXT
21. Bradley JF, Johnson RC, Goodman JL. The persistence of spirochetal nucleic acids in active Lyme arthritis. Ann Intern Med. 1994;120:487-488.
FREE FULL TEXT
22. Wormser GP. Duration of therapy for Lyme borreliosis. J Infect Dis. 1995;171:1379.
PUBMED
23. Goodman JL. Persistence of organisms for Lyme arthritis. Ann Intern Med. 1994;121:383-384.
FREE FULL TEXT
24. Lahesmaa R, Sharafelt M-C, Steinman L, Pekz G. Immunopathogenesis of human inflammatory arthritis: lessons from Lyme and reactive arthritis. J Infect Dis. 1994;170:978-985.
PUBMED
25. Steere AC, Dwyer E, Winshester R. Association of chronic Lyme arthritis with HLA-DR4 and HLADR2 alleles. N Engl J Med. 1990;323:219-223.
ABSTRACT
26. Caperton EM, Heim-Duthoy KL, Matzke GR, Peterson PK, Johnson RC. Ceftriaxone therapy of chronic inflammatory arthritis. Arch Intern Med. 1990;150:1677-1682.
FREE FULL TEXT
27. Hardin JA, Steere AC, Malawista. Immune complexes and the evolution of Lyme arthritis: dissemination and localization of abnormal C1q binding activity. N Engl J Med. 1979;301:1358-1363.
ABSTRACT
28. Sigal LM. Immunopathogenesis of Lyme borreliosis. Clin Dermatol. 1993:11:415-422.
PUBMED
29. Steere AC, Dwyer E, Winchester R. Immunogenic basis of chronic Lyme arthritis. N Engl J Med. 1990;219-223. 30. Kalish RA, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun. 1993;61:2774-2779.
FREE FULL TEXT
31. Fries JF, Hochberg MC, Medsyer TA Jr, Hunder GG, Bombardier C. Criteria for rheumatic disease, different types, and different functions. Arthritis Rheum. 1994;37:454-462.
PUBMED
32. Lightfoot RW, Luft BJ, Rahn DW, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: a cost-effectiveness analysis. Ann Intern Med. 1993;119:503-509.
FREE FULL TEXT
33. Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis. 1995;171:356-361.
PUBMED
34. Nadelman RB, Artlin Z, Wormser GP. Lifethreatening complications of empiric ceftriax-% one therapy for 'seronegative Lyme disease.' South Med J. 1991;84:1263-1264.
PUBMED
35. A Joint Statement of the American College of Rheumatology and the Council of the Infectious Diseases Society of America. Appropriateness of parenteral antibiotic treatment for patients with presumed Lyme disease. Ann Intern Med. 1993;119:518.
FREE FULL TEXT
|
